Results 21 to 30 of about 12,785,139 (351)

Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies

Medicina, 2023
Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a sudden and unexpected bleeding episode in a patient with no personal or family history of bleeding diathesis, and with a typical laboratory feature, i.e., a ...
Renato Marino
doaj   +1 more source

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.

New England Journal of Medicine, 2020
BACKGROUND Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients' quality of life. The half-life of recombinant factor VIII ranges from 15 to 19 hours because
B. Konkle, A. Shapiro, D. Quon, J. Staber, R. Kulkarni, M. Ragni, E. S. Chhabra, S. Poloskey, K. Rice, S. Katragadda, J. Fruebis, C. Benson   +11 more
semanticscholar   +1 more source

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Research and Practice in Thrombosis and Haemostasis, 2022
Background Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti ...
Claude Négrier, Johannes Oldenburg, Gili Kenet, Shannon L. Meeks, Jean‐Claude Bordet, Jens Müller, Sandra Le Quellec, Peter L. Turecek, Nikola Tripkovic, Yesim Dargaud   +9 more
doaj   +1 more source

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy

Frontiers in Immunology, 2020
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein.
Alex C. Chen, Xiaohe Cai, Chong Li, Liliane Khoryati, Marc A. Gavin, Carol H. Miao   +5 more
doaj   +1 more source

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia

Pilot and Feasibility Studies, 2018
Background The interest of health care agencies, private payers and policy makers for patient-reported outcomes (PRO) is continuously increasing. There is a substantial need to improve capacity to collect and interpret relevant PRO data to support ...
MW. Skinner, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, D. Noone, B. O’Mahony, D. Page, J. S. Stonebraker, A. Iorio   +9 more
doaj   +1 more source

CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY

Pakistan Armed Forces Medical Journal, 2021
Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patient receiving on demand treatment only. Study Design: Comparative cross sectional study.
Saima Zahir, Tahira Zafar, Altaf Hussain, Hamid Saeed Malik, Pervez Ahmed, Saleem Ahmed Khan   +5 more
doaj   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

Haematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat, Jules Russick, Bagirath Gangadharan, Julie Rayes, Mathieu Ing, Jan Voorberg, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +7 more
doaj   +1 more source

Purified factor VIII [PDF]

BMJ, 1995
Patients with haemophilia A lack only factor VIII. Why give them anything else as replacement treatment? Previously the answer to this question was determined largely by the practical difficulty in separating factor VIII from fibrinogen, fibronectin, and immunoglobulins, so that concentrates contained 2000 U/mg respectively, but concentrates prepared ...
Michael Laffan, Edward G. D. Tuddenham
openaire   +3 more sources

Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells

Frontiers in Immunology, 2020
The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients. Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on ...
Sandrine Delignat, Julie Rayes, Suryasarathi Dasgupta, Bagirath Gangadharan, Cécile V. Denis, Olivier D. Christophe, Jagadeesh Bayry, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +8 more
doaj   +1 more source

Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

Case Reports in Rheumatology, 2021
Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency
Christine Loftis, Emilia C. Dulgheru, Rosa White   +2 more
doaj   +1 more source